Effectiveness of methadone maintenance treatment in prevention of hepatitis C virus transmission among injecting drug users

Hepatitis Monthly

Volumn 13, Issue 8, 2013, Pages 9-

  Alavian, Seyed Moayed ^a,b   Mirahmadizadeh, Alireza ^c   Javanbakht, Mehdi ^d   Keshtkaran, Ali ^e   Heidari, Alireza ^e   Mashayekhi, Atefeh ^f   Salimi, Shima ^b   Hadian, Mohammad ^f  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Middle East Liver Disease Center   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e GOLESTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Effectiveness; Hepatitis C; Incidence; Iran; Maintenance; Methadone

Indexed keywords

METHADONE;

ADULT; ARTICLE; DRUG ABUSE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INJECTION; IRAN; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; PREVALENCE; RISK FACTOR; SELF REPORT; SENSITIVITY ANALYSIS; SEXUAL BEHAVIOR; THERAPY EFFECT; UNSAFE SEX; VIRUS TRANSMISSION;

EID: 84883149130     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/hepatmon.12411     Document Type: Article

References (41)

1. Sweeting MJ, De Angelis D, Brant LJ, Harris HE, Mann AG, Ramsay ME. The burden of hepatitis C in England. J Viral Hepat. 2007;14(8):570-6.
2. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology. 2008;48(2):418-31.
3. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144(10):705-14.
4. Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology. 1997;26(3 Suppl 1):15S-20S.
5. Hanafiah KM, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333-1342.
6. Aceijas C, Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy. 2007;18(5):352-8.
7. Kheirandish P, SeyedAlinaghi SA, Jahani M, Shirzad H, Ahmadian MS, Majidi A, et al. Prevalence and correlates of hepatitis C infection among male injection drug users in detention, Tehran, Iran. Journal of Urban Health. 2009;86(6):902-908.
8. Alavian SM, Ahmadzad-Asl M, Bagheri Lankarani K, Shahbabaie MA, Bahrami Ahmadi A, Kabir A. Hepatitis C infection in the general population of Iran: a systematic review. Hepat Mon. 2009;9(3):211-23.
9. Merat S, Rezvan H, Nouraie M, Jafari E, Abolghasemi H, Radmard AR, et al. Seroprevalence of hepatitis C virus: the first populationbased study from Iran. International Journal of Infectious Diseases. 2010;14:e113-e116.
10. Nokhodian Z, Meshkati M, Adibi P, Ataei B, Kassaian N, Yaran M, et al. Hepatitis C among Intravenous Drug Users in Isfahan, Iran: a Study of Seroprevalence and Risk Factors. Int J Prev Med. 2012;3(Suppl 1):S131-8.
11. Alavian SM, Fallahian F. Epidemiology of Hepatitis C in Iran and the World. Shiraz E Medical Journal. 2009;10(4):162-172.
12. Nasirian M, Doroudi F, Gooya MM, Sedaghat A, Haghdoost AA. Modeling of human immunodeficiency virus modes of transmission in iran. Journal of research in health sciences. 2012;12(2):81-87.
13. Rehle D, Leleux D, Erdelyi M, Tittel F, Fraser M, Friedfeld S. Ambient formaldehyde detection with a laser spectrometer based on difference-frequency generation in PPLN. Appl Phys B. 2001;72(8):947-52.
14. Bayoumi AM, Zaric GS. The cost-effectiveness of Vancouver's supervised injection facility. CMAJ. 2008;179(11):1143-51.
15. De Carli G, Puro V, Ippolito G. Risk of hepatitis C virus transmission following percutaneous exposure in healthcare workers. Infection. 2003;31 Suppl 2:22-7.
16. Vickerman P, Hickman M, Judd A. Modelling the impact on Hepatitis C transmission of reducing syringe sharing: London case study. Int J Epidemiol. 2007;36(2):396-405.
17. Terrault NA, Dodge JL, Murphy EL, Tavis JE, Kiss A, Levin TR, et al. Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study. Hepatology. 2013;57(3):881-9.
18. Wejstål Rune. Sexual transmission of hepatitis C virus. Journal of hepatology. 1999;31:92-95.
19. Holmes KK, Levine R, Weaver M. Effectiveness of condoms in pre-venting sexually transmitted infections. Bull World Health Organ. 2004;82(6):454-61.
20. Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev. 2002;1.
21. Zamani S, Ichikawa S, Nassirimanesh B, Vazirian M, Ichikawa K, Gouya MM, et al. Prevalence and correlates of hepatitis C virus infection among injecting drug users in Tehran. Int J Drug Policy. 2007;18(5):359-63.
22. Kassaian N, Ataei B, Yaran M, Babak A, Shoaei P. Hepatitis B and C among women with illegal social behavior in Isfahan, Iran: Seroprevalence and associated factors. Hepat Mon. 2011;11(5):368-71.
23. Nokhodian Z, Yazdani MR, Yaran M, Shoaei P, Mirian M, Ataei B, et al. Prevalence and Risk Factors of HIV, Syphilis, Hepatitis B and C Among Female Prisoners in Isfahan, Iran. Hepat Mon. 2012;12(7):442-7.
24. Nelson Paul K, Mathers Bradley M, Cowie Benjamin, Hagan Holly, Des Jarlais Don, Horyniak Danielle, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. The Lancet.;378(9791):571-583.
25. Gibson David R, Flynn Neil M, McCarthy John J. Effectiveness of methadone treatment in reducing HIV risk behavior and HIV seroconversion among injecting drug users. AIDS. 1999;13(14):1807-1818.
26. Gowing Linda, Farrell Michael F, Bornemann Reinhard, Sullivan Lynn E, Ali Robert. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2011;8.
27. Gowing LR, Hickman M, Degenhardt L. Mitigating the risk of HIV infection with opioid substitution treatment. Bull World Health Organ. 2013;91(2):148-9.
28. Strain EC, Bigelow GE, Liebson IA, Stitzer ML. Moderate-vs highdose methadone in the treatment of opioid dependence: a randomized trial. JAMA. 1999;281(11):1000-5.
29. Watkins KE, Metzger D, Woody G, McLellan AT. High-risk sexual behaviors of intravenous drug users in-and out-of-treatment: implications for the spread of HIV infection. Am J Drug Alcohol Abuse. 1992;18(4):389-98.
30. Alary Michel, Joly Jean R, Vincelette Jean, Lavoie René, Turmel Bruno, Remis Robert S. Lack of evidence of sexual transmission of hepatitis C virus in a prospective cohort study of men who have sex with men. American Journal of Public Health. 2005;95(3):502-505.
31. Garten RJ, Lai S, Zhang J, Liu W, Chen J, Vlahov D, et al. Rapid transmission of hepatitis C virus among young injecting heroin users in Southern China. Int J Epidemiol. 2004;33(1):182-8.
32. Marincovich B, Castilla J, del Romero J, Garcia S, Hernando V, Raposo M, et al. Absence of hepatitis C virus transmission in a prospective cohort of heterosexual serodiscordant couples. Sex Transm Infect. 2003;79(2):160-2.
33. Roy E, Haley N, Leclerc P, Boivin JF, Cedras L, Vincelette J. Risk factors for hepatitis C virus infection among street youths. CMAJ. 2001;165(5):557-60.
34. Dolan KA, Shearer J, White B, Zhou J, Kaldor J, Wodak AD. Fouryear follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection. Addiction. 2005;100(6):820-8.
35. Hagan H, Pouget ER, Des Jarlais DC. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J Infect Dis. 2011;204(1):74-83.
36. Lucidarme D, Bruandet A, Ilef D, Harbonnier J, Jacob C, Decoster A, et al. Incidence and risk factors of HCV and HIV infections in a cohort of intravenous drug users in the North and East of France. Epidemiol Infect. 2004;132(4):699-708.
37. Turner KM, Hutchinson S, Vickerman P, Hope V, Craine N, Palmateer N, et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction. 2011;106(11):1978-88.
38. van Beek I, Dwyer R, Dore GJ, Luo K, Kaldor JM. Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study. BMJ. 1998;317(7156):433-7.
39. Crofts N, Nigro L, Oman K, Stevenson E, Sherman J. Methadone maintenance and hepatitis C virus infection among injecting drug users. Addiction. 1997;92(8):999-1005.
40. Macalino GE, Celentano DD, Latkin C, Strathdee SA, Vlahov D. Risk behaviors by audio computer-assisted self-interviews among HIV-seropositive and HIV-seronegative injection drug users. AIDS Educ Prev. 2002;14(5):367-78.
41. Novick David M, Richman Beverly L, Friedman Jeffrey M, Friedman Jacqueline E, Fried Christine, Wilson Janifer P, et al. The medical status of methadone maintenance patients in treatment for 11-18 years. Drug and Alcohol Dependence. 1993;33(3):235-245.